Developer docs
API playgroundTry for free, no card

Search company profiles

Enzyme

Full company profile

uuid00095t9

Namestring
Enzyme
Legal namestring
Enzyme
Websiteurl
enzyme.finance
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Enzyme is a Zürich-headquartered (with UK operations via Avantgarde Finance Ltd) infrastructure provider for tokenized finance, founded in 2017 as Melon Protocol and rebranded to Enzyme in 2020. The platform enables institutions to issue, administer, and trade tokenized financial products — including tokenized hedge funds, money market funds, mutual funds, structured products, and on-chain options — through a suite of three core products: Enzyme Onyx (Vault-as-a-Service for fund issuance and administration), Enzyme Myso (on-chain covered calls and cash-secured puts), and Enzyme Blue (decentralized strategy management across 30+ DeFi protocols). The underlying technology is built on EVM-compatible chains and is being natively extended to the Canton Network and Rayls, with orchestration, valuation, and risk layers integrated via Chainlink (Runtime Environment, Proof of Reserve, Price Feeds) and Particula (RWA risk-intelligence framework).

The platform's modular architecture separates administrative functions (NAV reporting, compliance, investor onboarding, fee management) from execution layers, allowing white-label OEM embedding into customer platforms and integration with any custody or trading venue. Enzyme sells primarily to enterprise and institutional clients — asset managers, fund platforms, custodians, brokers, neobanks, family offices, and capital allocators (DAOs, foundations, treasuries) — via quote-based multi-year Onyx subscriptions, transaction and administration fees, and an SDK/API channel for developer-led integration. Distribution extends through channel partners such as exchanges and wallet providers, and through grant programs that allocate $MLN tokens to strategic builders. The company claims $7B+ in cumulative transaction volume, $200M+ in assets under technology, zero security breaches across 8+ years of operation, and time-to-launch of under 4 weeks from fund incorporation to execution. Compliance coverage spans MiFID, MiCA, AIFM, UCITS, SEC, and FCA frameworks.

Revenue is not publicly disclosed and the team is small (1-10 employees), consistent with an early-commercialization enterprise SaaS business. Recent strategic momentum is concentrated in 2025-2026 through partnerships with Chainlink, Particula, CV5 Capital, Canton Network, and Rayls — the latter two giving Enzyme direct distribution reach into Latin American banking infrastructure and into a Tier-1 institutional consortium respectively. Ownership remains private with a native $MLN token governance layer; no venture funding rounds are disclosed in the source data.

Short descriptiontext

Enzyme provides institutional-grade blockchain infrastructure for issuing, administering, and trading tokenized funds and on-chain options. It serves asset managers, fund platforms, custodians, brokers, and family offices via white-label Vault-as-a-Service products (Onyx, Myso, Blue) deployed across EVM, Canton, and Rayls networks.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersZürich, Switzerland
HQ citystring
Zürich
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tokenized finance infrastructure, vault-as-a-service, on-chain asset management, decentralized fund protocol, blockchain financial instruments
Industry4 codes
PRIMARYFSAGAMAA
Tokenization Platforms (RWA, Securities, Funds)
Financial & Insurance/Financial Technology (Fintech)/Blockchain & Web3 Financial Infrastructure (Tokenization, Custody Tech)
SECONDARYFSAPAEAJ
Tokenized Real-World Assets & On-Chain Treasuries (tokenized T-bills, money markets, cash management)
Financial & Insurance/Blockchain & Web3/DeFi & On-Chain Financial Services (lending, derivatives, stablecoins, payments)
SECONDARYFSAPAIAL
Interoperability & Integration Middleware (ERP/core banking connectors, messaging, APIs, cross-chain to permissioned)
Financial & Insurance/Blockchain & Web3/Enterprise Blockchain & Tokenization (permissioned networks, RWA tokenization)
SECONDARYFSAPAIAH
Compliance, Risk & RegTech for Tokenized Assets (KYC/AML, sanctions, travel rule, reporting)
Financial & Insurance/Blockchain & Web3/Enterprise Blockchain & Tokenization (permissioned networks, RWA tokenization)
NAICS code3 codes
  • Open-End Investment Funds525910
  • Funds, Trusts, and Other Financial Vehicles525
  • Financial Transactions Processing, Reserve, and Clearinghouse Activities522320
SIC code2 codes
  • Security & Commodity Brokers, Dealers, Exchanges & Services6200
  • Asset-Backed Securities6189
Product category
Tokenized Finance Infrastructure
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Vault-as-a-Service Platform Licensing
TypeSubscription Recurring
Description

Enzyme provides white-label Vault-as-a-Service infrastructure enabling enterprises to issue and administer tokenized funds and financial instruments. Revenue derived from platform licensing and technology fees associated with fund deployment, administration, and management.

enzyme.finance
2Transaction and Administration Fees
TypeTransaction Fee
Description

Fees associated with fund operations including subscriptions, redemptions, NAV reporting, fee management, and investor onboarding within the Onyx platform.

enzyme.finance
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1Enzyme Onyx Vault-as-a-Service pricing is enterprise quote-based
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Onyx pricing is not publicly disclosed on the website; a dedicated pricing page (/onyx-pricing) is referenced but specific tiers are not available in the scraped content. Contact sales for enterprise pricing.

enzyme.finance
2Grant Program for builders and managers
ModelFreemiumBilling cadenceAnnual
Notes

Enzyme may allocate $MLN tokens to selected projects based on strategic fit and potential impact, along with mentoring and long-term support. No monetary cost to recipients.

enzyme.finance
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Enzyme Onyx
Description

The complete technical stack for issuing, structuring, and administering tokenized funds and financial instruments. Provides institutional-grade infrastructure covering the full lifecycle of a tokenized vehicle including accounting, subscriptions, redemptions, NAV reporting, fee management, and investor onboarding.

enzyme.finance
+2 more records
Core offering1 text field

Enzyme provides blockchain-based institutional infrastructure for tokenized finance. Its core products include Enzyme Onyx (Vault-as-a-Service for issuing and administering tokenized funds), Enzyme Myso (on-chain covered calls and cash-secured puts protocol), and Enzyme Blue (decentralized strategy management platform interacting with 30+ protocols and hundreds of assets). The platform operates natively across EVM-compatible chains, Canton Network, and Rayls.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • $7B+ total transaction volume processed through the Enzyme protocol infrastructure
+5 more records
Product overview1 text field

Enzyme is a platform-plus-modules architecture providing global infrastructure for tokenized finance. The core offering consists of three main products: Enzyme Onyx (Vault as a Service for issuing and administering tokenized funds and instruments), Enzyme Myso (protocol for on-chain covered calls and cash-secured puts), and Enzyme Blue (end-to-end platform for decentralized strategy management). These products share the underlying Enzyme Vaults infrastructure and are available natively on both EVM-compatible chains and institutional networks like Canton and Rayls. Additional services include Distribution, Seeding and Investment, Advisory and Development, and Curation and Management support.

Product and service4 records
1Enzyme Onyx
CategoryVault-as-a-Service Platform
Description

Complete technical stack for issuing, structuring, and administering tokenized funds and financial instruments. Provides institutional-grade infrastructure covering the full lifecycle of tokenized vehicles including accounting, subscriptions, redemptions, NAV reporting, fee management, and investor onboarding, delivered in a white-label environment for fund platforms, custodians, brokers, and asset managers.

2Enzyme Myso
CategoryOn-Chain Derivatives Protocol
Description

Premier protocol for creating, trading, and managing fully customizable on-chain options strategies. Enables issuers and trading firms to create and sell bespoke covered calls and cash-secured puts with non-custodial settlement through automated marketplace or OTC. Configurable parameters include strike prices, expiries, auction mechanics, and premium structures.

3Enzyme Blue
CategoryDecentralized Strategy Management Platform
Description

End-to-end platform for decentralized strategy management. Interacts with 30+ DeFi protocols and hundreds of assets in one unified environment, with built-in analytics, delegation controls, and automation for managing tokenized and crypto strategies.

4Enzyme Vaults
CategoryVault Infrastructure
Description

Core vault infrastructure supporting all Enzyme products. Enzyme Vaults support all types of cryptocurrencies, real-world assets (RWA), and tokenized assets with protocol compatibility for seamless integration with leading DeFi protocols.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-08
Description

Enzyme joined Rayls as a launch partner, deploying Enzyme Onyx and Enzyme Myso natively on the Rayls network. Rayls is an EVM-compatible Layer 1 blockchain for financial institutions combining compliant public chain with private institutional nodes. Rayls selected by Central Bank of Brazil for Drex wholesale CBDC pilot and installed within 16 of the largest banks in the region.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-15
Description

Strategic product partnership integrating Enzyme Onyx with Particula's RWA risk-intelligence framework. Enables asset managers and product issuers to design, launch, and scale tokenized investment products with embedded independent risk ratings across structural design, counterparty risk, and underlying asset quality. Creates unified environment for risk-rated tokenized products on-chain.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

Strategic partnership with CV5 Capital, a leading regulated platform for launching institutional-grade hedge funds and digital asset funds in the Cayman Islands. CV5 will power new generation of regulated funds using Enzyme Onyx infrastructure.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-06
Description

Enzyme is integrating the Chainlink Runtime Environment (CRE), an orchestration layer for institutional-grade smart contract operations. CRE enables seamless administration of complex tokenized financial products across traditional and decentralized ecosystems, streamlining valuation and reporting across networks and data sources. Joint webinar hosted by Enzyme and Chainlink.

Strategic tierCoreTypeTechnology or Integration
Description

Enzyme Onyx and Enzyme Myso are being ported natively to the Canton Network. Canton is an institutional blockchain network launched by consortium including BNP Paribas, Goldman Sachs, Deutsche Börse, CBOE, and Moody's in 2023. Enzyme's expansion to Canton expected in early Q3 2026.

Strategic tierStrategicTypeTechnology or Integration
Description

Passif, a digital asset investment manager, built the Passif Alpha Fund — a tokenized hedge fund — on Enzyme Onyx. Fund engineered to preserve capital while enabling daily liquidity and real-time investor visibility into strategy activity.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Enzyme facilitated Stader Labs' Hyperloop distribution through Swissborg, demonstrating Enzyme's distribution network connecting Vault products with exchanges, wallet providers, and dApps.

Strategic tierStrategicTypeTechnology or Integration
Description

Chainlink Labs collaborated with Enzyme and Nexus Mutual to integrate Chainlink Proof of Reserve into Nexus Mutual's Enzyme Vault, enabling accurate valuation of ETH staking platform assets within the vault for NXMTY token pricing.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Tokeny is an institutional-grade tokenization platform offering white-label infrastructure for issuing, managing, and transferring tokenized securities. Closely comparable to Enzyme Onyx in target customer (fund issuers, asset managers) and EU regulatory focus (MiCA, MiFID).

TypeEmerging player
Description

Backed Finance issues tokenized securities tracking real-world assets (equities, bonds, ETFs) on public chains with full regulatory wrappers. Comparable to Enzyme Onyx for tokenized securities issuance, particularly for EU-distributed structured products.

3Lyra
TypeDirect peer
Description

Lyra is a leading on-chain options protocol for trading covered calls and cash-secured puts with automated market-making. Direct peer to Enzyme Myso, offering the same non-custodial options primitives to institutional and DeFi users.

TypeDirect peer
Description

Centrifuge provides infrastructure for tokenizing real-world assets (invoices, receivables, real estate) and connecting them to DeFi liquidity via the Tinlake protocol. Comparable to Enzyme Onyx's RWA tokenization use case with similar modular architecture for asset managers and issuers.

TypeDirect peer
Description

Maple Finance is an institutional on-chain credit marketplace with white-label lending infrastructure and fund administration capabilities. Comparable to Enzyme Onyx for tokenized private credit and structured fund vehicles, with a strong institutional lender base.

TypeBroad incumbent
Description

Ondo Finance provides tokenized US Treasuries, money market funds, and structured yield products with institutional-grade infrastructure. Comparable to Enzyme Onyx for tokenized RWA / treasury products but operates more as an issuer than a white-label infrastructure provider.

TypeDirect peer
Description

Securitize is a leading RWA and security token issuance platform with white-label fund issuance, transfer agent services, and institutional integrations. Directly comparable to Enzyme Onyx's Vault-as-a-Service for tokenized fund issuance, with a stronger focus on regulated US securities.

TypeDirect peer
Description

Polymath is one of the original security token platforms providing issuance, compliance, and identity infrastructure for tokenized securities. Comparable to Enzyme Onyx's compliance-ready tokenization focus, with a longer history but slower recent product velocity.

TypeEmerging player
Description

OpenEden is a regulated tokenized T-bills and money market platform focused on bringing US Treasury exposure on-chain. Comparable to Enzyme Onyx's tokenized treasury and money market fund use cases, but more narrowly focused on yield-bearing RWA.

TypeEmerging player
Description

Archax is a FCA-regulated digital asset exchange, broker, and custodian in the UK offering end-to-end infrastructure for tokenized securities. Comparable to Enzyme Onyx as an institutional tokenization platform with strong UK regulatory positioning, though Archax operates its own exchange and custody.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration10 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Enzyme

Tokenized Finance Infrastructureenzyme.finance

Enzyme provides institutional-grade blockchain infrastructure for issuing, administering, and trading tokenized funds and on-chain options. It serves asset managers, fund platforms, custodians, brokers, and family offices via white-label Vault-as-a-Service products (Onyx, Myso, Blue) deployed across EVM, Canton, and Rayls networks.

What Enzyme does

Enzyme is a Zürich-headquartered (with UK operations via Avantgarde Finance Ltd) infrastructure provider for tokenized finance, founded in 2017 as Melon Protocol and rebranded to Enzyme in 2020. The platform enables institutions to issue, administer, and trade tokenized financial products — including tokenized hedge funds, money market funds, mutual funds, structured products, and on-chain options — through a suite of three core products: Enzyme Onyx (Vault-as-a-Service for fund issuance and administration), Enzyme Myso (on-chain covered calls and cash-secured puts), and Enzyme Blue (decentralized strategy management across 30+ DeFi protocols). The underlying technology is built on EVM-compatible chains and is being natively extended to the Canton Network and Rayls, with orchestration, valuation, and risk layers integrated via Chainlink (Runtime Environment, Proof of Reserve, Price Feeds) and Particula (RWA risk-intelligence framework).

The platform's modular architecture separates administrative functions (NAV reporting, compliance, investor onboarding, fee management) from execution layers, allowing white-label OEM embedding into customer platforms and integration with any custody or trading venue. Enzyme sells primarily to enterprise and institutional clients — asset managers, fund platforms, custodians, brokers, neobanks, family offices, and capital allocators (DAOs, foundations, treasuries) — via quote-based multi-year Onyx subscriptions, transaction and administration fees, and an SDK/API channel for developer-led integration. Distribution extends through channel partners such as exchanges and wallet providers, and through grant programs that allocate $MLN tokens to strategic builders. The company claims $7B+ in cumulative transaction volume, $200M+ in assets under technology, zero security breaches across 8+ years of operation, and time-to-launch of under 4 weeks from fund incorporation to execution. Compliance coverage spans MiFID, MiCA, AIFM, UCITS, SEC, and FCA frameworks.

Revenue is not publicly disclosed and the team is small (1-10 employees), consistent with an early-commercialization enterprise SaaS business. Recent strategic momentum is concentrated in 2025-2026 through partnerships with Chainlink, Particula, CV5 Capital, Canton Network, and Rayls — the latter two giving Enzyme direct distribution reach into Latin American banking infrastructure and into a Tier-1 institutional consortium respectively. Ownership remains private with a native $MLN token governance layer; no venture funding rounds are disclosed in the source data.

Enzyme firmographics

Firmographics
Name
Enzyme
Legal name
Enzyme
Website
https://enzyme.finance
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Enzyme provides institutional-grade blockchain infrastructure for issuing, administering, and trading tokenized funds and on-chain options. It serves asset managers, fund platforms, custodians, brokers, and family offices via white-label Vault-as-a-Service products (Onyx, Myso, Blue) deployed across EVM, Canton, and Rayls networks.
Ownership category
akta.pro rank

Enzyme industry classification

Industry
Product category
Tokenized Finance Infrastructure
NAICS
Open-End Investment Funds (525910), Funds, Trusts, and Other Financial Vehicles (525), Financial Transactions Processing, Reserve, and Clearinghouse Activities (522320)
SIC
Security & Commodity Brokers, Dealers, Exchanges & Services (6200), Asset-Backed Securities (6189)
akta.pro industry
PRIMARYFSAGAMAA
Tokenization Platforms (RWA, Securities, Funds)
Financial & Insurance/Financial Technology (Fintech)/Blockchain & Web3 Financial Infrastructure (Tokenization, Custody Tech)
SECONDARYFSAPAEAJ
Tokenized Real-World Assets & On-Chain Treasuries (tokenized T-bills, money markets, cash management)
Financial & Insurance/Blockchain & Web3/DeFi & On-Chain Financial Services (lending, derivatives, stablecoins, payments)
SECONDARYFSAPAIAL
Interoperability & Integration Middleware (ERP/core banking connectors, messaging, APIs, cross-chain to permissioned)
Financial & Insurance/Blockchain & Web3/Enterprise Blockchain & Tokenization (permissioned networks, RWA tokenization)
SECONDARYFSAPAIAH
Compliance, Risk & RegTech for Tokenized Assets (KYC/AML, sanctions, travel rule, reporting)
Financial & Insurance/Blockchain & Web3/Enterprise Blockchain & Tokenization (permissioned networks, RWA tokenization)

Keywords

  • Tokenized finance infrastructure
  • Vault-as-a-service
  • On-chain asset management
  • Decentralized fund protocol
  • Blockchain financial instruments

Where Enzyme is headquartered

Location

Headquarters

HQ city
Zürich
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Enzyme business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Vault-as-a-Service Platform Licensing: Enzyme provides white-label Vault-as-a-Service infrastructure enabling enterprises to issue and administer tokenized funds and financial instruments. Revenue derived from platform licensing and technology fees associated with fund deployment, administration, and management.
  2. Transaction and Administration Fees: Fees associated with fund operations including subscriptions, redemptions, NAV reporting, fee management, and investor onboarding within the Onyx platform.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnzyme Onyx Vault-as-a-Service pricing is enterprise quote-based
FreemiumAnnualGrant Program for builders and managers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Enzyme product offering

Product offering

Core offering

Enzyme provides blockchain-based institutional infrastructure for tokenized finance. Its core products include Enzyme Onyx (Vault-as-a-Service for issuing and administering tokenized funds), Enzyme Myso (on-chain covered calls and cash-secured puts protocol), and Enzyme Blue (decentralized strategy management platform interacting with 30+ protocols and hundreds of assets). The platform operates natively across EVM-compatible chains, Canton Network, and Rayls.

Product overview

Enzyme is a platform-plus-modules architecture providing global infrastructure for tokenized finance. The core offering consists of three main products: Enzyme Onyx (Vault as a Service for issuing and administering tokenized funds and instruments), Enzyme Myso (protocol for on-chain covered calls and cash-secured puts), and Enzyme Blue (end-to-end platform for decentralized strategy management). These products share the underlying Enzyme Vaults infrastructure and are available natively on both EVM-compatible chains and institutional networks like Canton and Rayls. Additional services include Distribution, Seeding and Investment, Advisory and Development, and Curation and Management support.

Differentiator

Problem solved

Functional benefit

Brands

  • Enzyme Onyx: The complete technical stack for issuing, structuring, and administering tokenized funds and financial instruments. Provides institutional-grade infrastructure covering the full lifecycle of a tokenized vehicle including accounting, subscriptions, redemptions, NAV reporting, fee management, and investor onboarding.
  • Enzyme Myso
  • Enzyme Blue

Products and services

  • Enzyme Onyx Complete technical stack for issuing, structuring, and administering tokenized funds and financial instruments. Provides institutional-grade infrastructure covering the full lifecycle of tokenized vehicles including accounting, subscriptions, redemptions, NAV reporting, fee management, and investor onboarding, delivered in a white-label environment for fund platforms, custodians, brokers, and asset managers.
  • Enzyme Myso Premier protocol for creating, trading, and managing fully customizable on-chain options strategies. Enables issuers and trading firms to create and sell bespoke covered calls and cash-secured puts with non-custodial settlement through automated marketplace or OTC. Configurable parameters include strike prices, expiries, auction mechanics, and premium structures.
  • Enzyme Blue End-to-end platform for decentralized strategy management. Interacts with 30+ DeFi protocols and hundreds of assets in one unified environment, with built-in analytics, delegation controls, and automation for managing tokenized and crypto strategies.
  • Enzyme Vaults Core vault infrastructure supporting all Enzyme products. Enzyme Vaults support all types of cryptocurrencies, real-world assets (RWA), and tokenized assets with protocol compatibility for seamless integration with leading DeFi protocols.

Quantifiable outcome

  • $7B+ total transaction volume processed through the Enzyme protocol infrastructure
  • +5 more outcomes

Companies that use Enzyme

Customer profile

Named customers8 records

Segments5 records

Ideal customer profiles4 records

Enzyme technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration10 records

Feature8 records

Enzyme partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, strategic and minor.

  • RaylscoreTechnology or Integration · 8 May 2026Enzyme joined Rayls as a launch partner, deploying Enzyme Onyx and Enzyme Myso natively on the Rayls network. Rayls is an EVM-compatible Layer 1 blockchain for financial institutions combining compliant public chain with private institutional nodes. Rayls selected by Central Bank of Brazil for Drex wholesale CBDC pilot and installed within 16 of the largest banks in the region.
  • ParticulacoreStrategic or Co-development Partner · 15 December 2025Strategic product partnership integrating Enzyme Onyx with Particula's RWA risk-intelligence framework. Enables asset managers and product issuers to design, launch, and scale tokenized investment products with embedded independent risk ratings across structural design, counterparty risk, and underlying asset quality. Creates unified environment for risk-rated tokenized products on-chain.
  • CV5 CapitalstrategicStrategic or Co-development Partner · 18 November 2025Strategic partnership with CV5 Capital, a leading regulated platform for launching institutional-grade hedge funds and digital asset funds in the Cayman Islands. CV5 will power new generation of regulated funds using Enzyme Onyx infrastructure.
  • ChainlinkcoreTechnology or Integration · 6 November 2025Enzyme is integrating the Chainlink Runtime Environment (CRE), an orchestration layer for institutional-grade smart contract operations. CRE enables seamless administration of complex tokenized financial products across traditional and decentralized ecosystems, streamlining valuation and reporting across networks and data sources. Joint webinar hosted by Enzyme and Chainlink.
  • Canton NetworkcoreTechnology or IntegrationEnzyme Onyx and Enzyme Myso are being ported natively to the Canton Network. Canton is an institutional blockchain network launched by consortium including BNP Paribas, Goldman Sachs, Deutsche Börse, CBOE, and Moody's in 2023. Enzyme's expansion to Canton expected in early Q3 2026.
  • PassifstrategicTechnology or IntegrationPassif, a digital asset investment manager, built the Passif Alpha Fund — a tokenized hedge fund — on Enzyme Onyx. Fund engineered to preserve capital while enabling daily liquidity and real-time investor visibility into strategy activity.
  • SwissborgminorChannel Partner/ Reseller/ DistributorEnzyme facilitated Stader Labs' Hyperloop distribution through Swissborg, demonstrating Enzyme's distribution network connecting Vault products with exchanges, wallet providers, and dApps.
  • Chainlink LabsstrategicTechnology or IntegrationChainlink Labs collaborated with Enzyme and Nexus Mutual to integrate Chainlink Proof of Reserve into Nexus Mutual's Enzyme Vault, enabling accurate valuation of ETH staking platform assets within the vault for NXMTY token pricing.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Enzyme competitors and assessment

Company assessment

Direct peers

  • Tokeny: Tokeny is an institutional-grade tokenization platform offering white-label infrastructure for issuing, managing, and transferring tokenized securities. Closely comparable to Enzyme Onyx in target customer (fund issuers, asset managers) and EU regulatory focus (MiCA, MiFID).
  • Lyra: Lyra is a leading on-chain options protocol for trading covered calls and cash-secured puts with automated market-making. Direct peer to Enzyme Myso, offering the same non-custodial options primitives to institutional and DeFi users.
  • Centrifuge: Centrifuge provides infrastructure for tokenizing real-world assets (invoices, receivables, real estate) and connecting them to DeFi liquidity via the Tinlake protocol. Comparable to Enzyme Onyx's RWA tokenization use case with similar modular architecture for asset managers and issuers.
  • Maple Finance: Maple Finance is an institutional on-chain credit marketplace with white-label lending infrastructure and fund administration capabilities. Comparable to Enzyme Onyx for tokenized private credit and structured fund vehicles, with a strong institutional lender base.
  • Securitize: Securitize is a leading RWA and security token issuance platform with white-label fund issuance, transfer agent services, and institutional integrations. Directly comparable to Enzyme Onyx's Vault-as-a-Service for tokenized fund issuance, with a stronger focus on regulated US securities.
  • Polymath: Polymath is one of the original security token platforms providing issuance, compliance, and identity infrastructure for tokenized securities. Comparable to Enzyme Onyx's compliance-ready tokenization focus, with a longer history but slower recent product velocity.

Emerging players

  • Backed Finance: Backed Finance issues tokenized securities tracking real-world assets (equities, bonds, ETFs) on public chains with full regulatory wrappers. Comparable to Enzyme Onyx for tokenized securities issuance, particularly for EU-distributed structured products.
  • OpenEden: OpenEden is a regulated tokenized T-bills and money market platform focused on bringing US Treasury exposure on-chain. Comparable to Enzyme Onyx's tokenized treasury and money market fund use cases, but more narrowly focused on yield-bearing RWA.
  • Archax: Archax is a FCA-regulated digital asset exchange, broker, and custodian in the UK offering end-to-end infrastructure for tokenized securities. Comparable to Enzyme Onyx as an institutional tokenization platform with strong UK regulatory positioning, though Archax operates its own exchange and custody.

Broad incumbents

  • Ondo Finance: Ondo Finance provides tokenized US Treasuries, money market funds, and structured yield products with institutional-grade infrastructure. Comparable to Enzyme Onyx for tokenized RWA / treasury products but operates more as an issuer than a white-label infrastructure provider.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Enzyme social profiles

Digital presence

Enzyme compliance and trust

Trust signal

Compliance8 records

Enzyme financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Enzyme leadership team

Management profile

Number of profiles

Profiles1 record

Enzyme funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Enzyme M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enzyme

What does Enzyme do?

Enzyme provides blockchain-based institutional infrastructure for tokenized finance. Its core products include Enzyme Onyx (Vault-as-a-Service for issuing and administering tokenized funds), Enzyme Myso (on-chain covered calls and cash-secured puts protocol), and Enzyme Blue (decentralized strategy management platform interacting with 30+ protocols and hundreds of assets). The platform operates natively across EVM-compatible chains, Canton Network, and Rayls.

Is Enzyme a public or private company?

Enzyme is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Enzyme founded?

Enzyme was founded in 2017. It employs 11 to 50 people.

Where is Enzyme based?

Enzyme is headquartered in Zürich, Switzerland, in the Europe region.

How does Enzyme make money?

Two revenue lines are on record. Vault-as-a-Service Platform Licensing is the primary driver. The others are transaction and Administration Fees.

Who are Enzyme's main competitors?

Direct peers on record are Tokeny, Lyra, Centrifuge, Maple Finance, Securitize and Polymath. Emerging players are Backed Finance, OpenEden and Archax. Ondo Finance is listed as a broad incumbent.

Does Enzyme have an API?

Yes. Enzyme offers APIs and SDKs for developers to build on its platform. The developer hub provides documentation for integration purposes. The platform supports white-label integration with customizable page and domain name, white-label front-end integration, and 1-click deposit functionality. Developer documentation is at docs.enzyme.finance.

What industry is Enzyme in?

Enzyme's product category is Tokenized Finance Infrastructure. Its primary akta.pro industry code is FSAGAMAA, Tokenization Platforms (RWA, Securities, Funds), with a secondary code of FSAPAEAJ, Tokenized Real-World Assets & On-Chain Treasuries (tokenized T-bills, money markets, cash management). Its NAICS code is 525910 and its SIC code is 6200.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinanceFeeds5 Automated Treasury Tools for Multichain Crypto StartupsFive automated treasury tools for multichain crypto startups are profiled, including Eco Routes, Sphere, Enzyme, Safe, and Fireblocks. The tools offer cross-chain stablecoin movement, automated sweeps, and custody layers, with guidance on selecting based on coverage, automation, and security. Automation does not remove treasury risk, and human oversight is recommended.Markets DailyEnzyme (MLN) Reaches Self Reported Market Cap of $3.95 MillionEnzyme (MLN) reached a self-reported market capitalization of $3.95 million following an 8.7% price increase against the US dollar on August 20th. The cryptocurrency traded approximately $1.34 million in volume over the last day, with its token price standing at roughly $1.33. Enzyme operates as a smart contract-enforced platform for building and scaling investment strategies.TradingViewEnzyme to Deprecate GMX Integration on August 17thEnzyme will deprecate its GMX integration on Enzyme Blue on August 17th, requiring vaults using GMX to liquidate positions and withdraw funds before the deadline. This operational change affects users of the decentralized protocol built on Ethereum for on-chain asset management.PR NewswireCV5 Capital Partners with Enzyme to Deliver Institutional-Grade Tokenized Fund SolutionsCV5 Capital, an institutional platform for digital asset and tokenized fund launches, has announced a strategic partnership with Enzyme, a global infrastructure provider for tokenized finance, to adopt Enzyme Onyx as the foundational technology stack for issuing and administering tokenized fund offerings for professional and institutional investors. The partnership combines CV5 Capital's regulated Cayman fund infrastructure with Enzyme's decentralized asset management technology to create fund structures supporting cryptocurrencies, securities, commodities, and real-world assets. The initial focus will be on launching tokenized fund strategies including market-neutral digital asset funds, Bitcoin treasury vehicles, and tokenized credit opportunities under the CV5 Digital SPC umbrella.LexrM&A Strategies for DAOs and DeFi in Web3An explainer article outlines how mergers and acquisitions are being conducted in the Web3 space, citing Arbitrum DAO's $100-250 million M&A unit and Enzyme Finance's interest. It argues token swaps, rather than share or asset deals, are the standard mechanism for aligning incentives, gaining control, and funding acquisitions. The piece also flags due diligence, regulatory, tax, and investor alignment risks.BenzingaEnzyme, Shiba Inu, KuCoin — 3 Altcoins Seeing High Social Media Interest Today - Amazon.com (NASDAQ:AMZN)Three altcoins—Enzyme (MLN), Shiba Inu (SHIB), and KuCoin Token (KCS)—attracted high social media interest on Tuesday, with each posting significant weekly gains ranging from 5.84% to 50.7%. Enzyme announced integration with Yearn Vaults for yield farming and saw its token listed on Coinbase Pro, while Shiba Inu became the most-mentioned cryptocurrency on Twitter and expanded usability through Shopping.io to allow spending at Amazon, eBay, and Walmart retailers. KuCoin Token gained 30.45% amid a token burn initiative reducing total supply and a weekend giveaway tied to the EURO2020 soccer championships.GlobeNewswireTechemy Capital and Enzyme Finance Partner to Launch Holistic ETH-BTC PortfolioTechemy Capital launched its Holistic ETH-BTC Portfolio with Enzyme Finance, using Brave New Coin's data infrastructure. The actively traded portfolio uses long and short strategies on Bitcoin and Ethereum, with non-custodial storage and 98% lower administrative costs. Techemy will later roll out a Managed DeFi Portfolio.